期刊文献+

多西他赛对人子宫内膜腺癌Ishikawa细胞凋亡诱导的实验研究

Experimental Study on Docetaxel-induced Apoptosis of Human Endometrial Adenocarcinoma Ishikawa Cells
下载PDF
导出
摘要 目的探讨多西他赛对体外培养的人子宫内膜腺癌Ishikawa细胞凋亡的诱导作用。方法体外培养Ishikawa细胞,不同浓度的多西他赛作用48 h后,用MTT法和流式细胞术检测多西他赛对Ishikawa细胞增殖和细胞周期的影响。结果多西他赛对Ishikawa细胞的增殖具有明显抑制作用,呈剂量依赖性(P〈0.05)。多西他赛引起细胞阻滞在G1~S期,细胞凋亡率增加,呈剂量依赖性(P〈0.05)。结论人子宫内膜腺癌Ishikawa细胞对多西他赛具有药物敏感性,多西他赛对人子宫内膜腺癌Ishikawa细胞的杀伤作用是通过诱导细胞凋亡途径实现的。 Objective To investigate the in vitro effects of docetaxel on proliferation and apoptosis of cultured human endometrial adenocar- cinoma Ishikawa cells. Methods Human endometrial adenocarcinoma Ishikawa cells were cultured in vitro and treated with different con- cenlxation of doeetaxel for 48 h respectively ; MTT assay and flow cytometry were used to measure the effects of docetaxel on cell proliferation and cell cycle. Results Docetaxel inhibited cell proliferation of cultured Ishikawa cells in a dose dependent manner (P 〈 0.05 ). Docetaxel blocked the cell cycle in G1-S period and increased the rates of cell apoptosis in a dose dependent manner (P 〈 0.05 ). Conclusion Doc- etaxel is effective for inhibiting the growth of endometrial adenocarcinoma Ishikawa cells. This anti-neoplastic effect may function through cell cycle arrest in G1-S period and increased cell apoptosis.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2012年第8期716-718,共3页 Journal of China Medical University
基金 沈阳市科技局资助项目(F10-205-1-58)
关键词 多西他赛 多西紫杉醇 子宫内膜腺癌 子宫内膜癌 细胞凋亡 ISHIKAWA细胞 docetaxel taxotere endometrial adenocarcinoma endometrial cancer apoptosis Ishikawa cell
  • 相关文献

参考文献10

二级参考文献18

  • 1翟友刚,史朋,谢忠平.p21^(WAF1/CIP1)基因与肿瘤[J].生命的化学,2004,24(6):505-507. 被引量:4
  • 2Ludwig H, Khayat D, Giaccone G, et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies [J]. Cancer, 2005, 104(9): 1794-807. 被引量:1
  • 3Berkers CR, Ovaa H. Drug discovery and assay development in the ubiquitin-proteasome system [ J ]. Biochem Soc Trans, 2010, 38 (Pt 1): 14-20. 被引量:1
  • 4Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours[J]. Eur J Cancer, 2007, 43 (7): 1125-33. 被引量:1
  • 5Ozaki S, Tanaka O, Fujii S, et al. Therapywith bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma[J]. Int J Hematol, 2007, 86(2): 180-5. 被引量:1
  • 6O'Connor OA, Portlock C, Moskowitz C, et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes [J]. Clin Cancer Res, 2010, 16(2): 719-26. 被引量:1
  • 7Bauer S, Parry JA, Muhlenberg T, et al. Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells [J]. Cancer Res, 2010, 70(1): 150-9. 被引量:1
  • 8Davies AM, Ruel C, Lara PN, et al. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study[J]. J Thorac Oncol, 2008, 3(1): 68-74. 被引量:1
  • 9Ramirez PT, Landen CN Jr, Coleman RL, et al. Phase I trial of the proteaxsome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer [J]. Gynecol Oncol, 2008, 108(1): 68-71. 被引量:1
  • 10Shi J, Tricot G J, Garg TK, et al. Bortezomib down-regulates the cell surface expression of HLA-class I and enhances natural killer cell-mediated lysis ofmyeloma[J]. Blood, 2008, 111(3): 1309-17. 被引量:1

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部